16917-43-4

Basic information

• Product Name: (1E)-1-benzylidene-2-(4-bromophenyl)hydrazine
• Synonyms: Benzaldehyde, 2-(4-bromophenyl)hydrazone
• CAS NO: 16917-43-4
• Molecular Formula: C₁₃H₁₁BrN₂
• Molecular Weight: 275.1438
• Mol File: 16917-43-4.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 371.461°C at 760 mmHg
• Flash Point: 178.454°C
• Density: 1.33g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.603
• CAS DataBase Reference: (1E)-1-benzylidene-2-(4-bromophenyl)hydrazine(CAS DataBase Reference)
• NIST Chemistry Reference: (1E)-1-benzylidene-2-(4-bromophenyl)hydrazine(16917-43-4)
• EPA Substance Registry System: (1E)-1-benzylidene-2-(4-bromophenyl)hydrazine(16917-43-4)

Safety Data

• Hazardous Substances Data: 16917-43-4(Hazardous Substances Data)

Upstream product

• 41931-18-4 (4-bromophenyl)hydrazine hydrochloride salt 
• 100-52-7 benzaldehyde 
• 103-02-6 acetone phenylhydrazone 
• 622-88-8 4-bromophenylhydrazine hydrochloride 
• 56-23-5 tetrachloromethane 
• 7726-95-6 bromine 
• 588-64-7 benzaldehyde phenylhydrazone 
• 589-21-9 (4-bromophenyl)hydrazine 

Downstream Products

• 59635-31-3 2-(4-bromophenyl)-5-phenyl-2H-tetrazole 
• 72437-42-4 [(4-bromophenyl)diazenyl](phenyl)methyl hydroperoxide 
• 2516-46-3 N-α-bromobenzylidene-N'-2,4-dibromophenylhydrazine 
• 929606-98-4 1-(4-bromophenyl)-5-methyl-3-phenyl-1H-pyrazole 
• 1077-94-7 5-bromobenzopyrazole-3-carboxylic acid 
• 1246462-22-5 1-(4-bromophenyl)-3,5-diphenyl-1H-1,2,4-triazole 
• 26254-21-7 [2-(4-bromo-phenyl)-5-phenyl-2H-[1,2,4]triazol-3-yl]-methanol 
• 58954-05-5 1-(4-bromophenyl)-3,5-diphenyl-1H-pyrazole 
• 1122-91-4 4-bromo-benzaldehyde 
• 1416008-62-2 tert-butyl 2'-(4-bromophenyl)-4'-tert-butyl-2-oxo-5'-phenyl-2',4'-dihydrospiro[indoline-3,3'-pyrazole]-1-carboxylate 

Relevant articles and documents

Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity

Histone deacetylase 6 (HDAC6) has emerged as a critical regulator of many cellular pathways in tumors due to its unique structure basis and abundant substrate types. Over the past few decades, the role played by HDAC6 inhibitors as anticancer agents has sparked great interest of biochemists worldwide. However, they were less reported for gastric cancer therapy. In this paper, with the help of bioisosteric replacement, in-house library screening, and lead optimization strategies, we designed, synthesized and verified a series of 1,3-diaryl-1,2,4-triazole-capped HDAC6 inhibitors with promising anti-gastric cancer activities. Amongst, compound 9r displayed the best inhibitory activity towards HDAC6 (IC50 = 30.6 nM), with 128-fold selectivity over HDAC1. Further BLI and CETSA assay proved the high affinity of 9r to HDAC6. In addition, 9r could dose-dependently upregulate the levels of acetylated α-tubulin, without significant effect on acetylated histone H3 in MGC803 cells. Besides, 9r exhibited potent antiproliferative effect on MGC803 cells, and promoted apoptosis and suppressed the metastasis without obvious toxicity, suggesting 9r would serve as a potential lead compound for the development of novel therapeutic agents of gastric cancer.

Sequential [3+2] annulation reaction of prop-2-ynylsulfonium salts and hydrazonyl chlorides: Synthesis of pyrazoles containing functional motifs

A novel sequential [3+2] annulation reaction has been developed using prop-2-ynylsulfonium salts and hydrazonyl chlorides, affording a series of pyrazoles with functional motifs that can be post modified in the preparation of various drugs or drug candidates. Further transformation and gram-scale operations could also be achieved efficiently. This journal is

Synthesis of hybrid polycycles containing fused hydroxy benzofuran and 1H-indazoles via a domino cyclization reaction

A stoichiometry controlled domino cyclization reaction of hydrazone and p-benzoquinone to an angularly fused 3H-benzofuro[3,2-e]indazole core with an embedded oxygenated dibenzofuran framework under mild reaction conditions is disclosed. The reaction involves palladium catalyzed 5-hydroxy-1H-indazole formation followed by TFA mediated [3+2] annulation between the in situ formed 5-hydroxy-1H-indazole and p-benzoquinone. The developed method is attractive because of the concomitant formation of two heterocyclic rings with consecutive multiple bond forming events that include two C-C, one C-N and one C-O bonds. Spectroscopic and theoretical studies of the blue emissive benzofuroindazole derivatives have also been described.